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Abstract
Antibiotic use in the treatment of respiratory tract infections is common in primary care. The European Surveillance of Antimicrobial
Consumption (ESAC programme), collecting data from 35 countries, showed that antibiotic use was highest in southern European coun-
tries. Increased antibiotic consumption has been shown by numerous ecological studies to contribute to the emergence of antibiotic
resistance in streptococci. A study comparing outpatient antibiotic consumption in the USA showed it to be similar to that in southern
European countries, but macrolides, particularly azithromycin, are among the first-line agents prescribed in the USA for respiratory
infections. In Europe, patients are more likely to receive a b-lactam; and when a macrolide is indicated, clarithromycin is more likely to
be prescribed than azithromycin. Streptococci resistance to macrolides can be acquired via two mechanisms: by the mef gene, which
encodes for the efflux pump mechanism, producing low to moderate resistance, or the erm gene (post-transcriptional modification of
the bacterial ribosomal unit), resulting in high resistance. Macrolide resistance is mediated by erm(B) and mef(A) alone or in combina-
tion. A surveillance study showed that mef was responsible for most of the macrolide resistance seen in the USA; a decrease in the
number of isolates carrying mef(A) was associated with a doubling of the number of isolates carrying both mef(A) and erm(B). Higher
consumption of clarithromycin in Europe correlated with a predominance of erm(B)-carrying Streptococcus pneumoniae. The erm(B) gene
caused resistance in 84% of the isolates in Europe.
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Introduction
Antibiotic usage in primary healthcare settings is high, and
respiratory tract infections are the most common indications
for use [1]. Macrolides are often prescribed for respiratory
infections caused by Gram-positive organisms such as Strepto-
coccus species [2]. Numerous ecological studies have con-
firmed that increased antibiotic consumption has led to the
emergence of antibiotic resistance worldwide [3,4]. In addi-
tion to antibiotic use, other factors contributing to the
emergence of resistance include dose and duration of antibi-
otic therapy and cross-selection, e.g. cross-selection of resis-
tance and cross-selection between b-lactam–tetracycline–
macrolide resistance.
Streptococci acquire resistance to macrolides via two
mechanisms. The first is the efflux pump mechanism encod-
ed by the mef (macrolide efflux) gene. Low to moderate
resistance to macrolides develops with a minimum inhibitory
concentration (MIC) of erythromycin ranging from 0.5
to 32 mg/L. The second mechanism of resistance is post-
transcriptional modification of the bacterial ribosome subunit
by methylase encoded by the erm gene. This results in high
resistance, with an MIC of erythromycin ranging from 32 to
>512 mg/L [2,4].
The worldwide problem of antibiotic resistance requires
combined international efforts, as geographical differences
exist in the rates of resistance to various classes of antibiot-
ics. Differential selection pressure is thought to be responsi-
ble for this geographical difference. Hence, monitoring of
antibiotic usage should accompany surveillance programmes
for antibiotic resistance [2,3].
Antibiotic Use in Europe and the USA
The European Surveillance of Antimicrobial Consumption
(ESAC) is an international network of national surveillance
systems that collects comparable and reliable data on antibi-
otic use. This project was funded by grants from DG/
SANCO of the European Commission. For the first time, it
provided a comprehensive database of internationally compa-
rable data on antibacterial consumption in Europe by outpa-
tients and inpatients [1,3,5].
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Thirty-five countries participate in the ESAC project. The
participants comprise 27 European Union member states,
Croatia and Turkey as applicants, and six other countries
(Former Yugoslav Republic of Macedonia, Iceland, Israel,
Norway, Russia and Switzerland) that have recently joined
the project [5,6].
A study compared outpatient antibiotic consumption in
the USA with data from the ESAC. The results showed that
antibiotic use, defined by daily doses/1000 inhabitants/day,
was high in southern European countries. The highest
consumption was observed in Greece, France and Italy.
Northern European countries reported comparably lower
antibiotic use, with The Netherlands reporting the least
consumption. Outpatient systemic antibiotic use in the USA
was similar to that in southern European countries [3].
The difference in outpatient macrolide, lincosamide and
streptogramin (MLS) use between the USA and Europe may
be due to variations in the types of infection treated in these
countries. In the USA, macrolides are among the first-line
agents prescribed for respiratory infections, and treatment
guidelines approve macrolides for infections due to atypical
pathogens. In Europe, atypical infections, e.g. those caused by
Mycoplasma and Chlamydia, are considered less clinically rele-
vant, and since the emergence of macrolide resistance poses
a considerable clinical threat, patients with these infections
would probably receive a b-lactam [7]. A comparison of out-
patient MLS use according to corresponding antibiotic sub-
class and defined daily dose in Europe and the USA is
presented in Table 1 [3].
Ecological Evidence for the Link between
Antibiotic Use and Resistance in
Streptococcus pneumoniae
Numerous studies have shown an association, but not a
causal link, between antibiotic consumption and resistance. A
study was conducted to analyse the ecological association
between antibiotic use and antibiotic resistance rates [1].
Antibiotic susceptibility data were collected from the Euro-
pean Antimicrobial Resistance Surveillance System project,
the telithromycin surveillance (PROTEKT) project, and the
pan-European project. A correlation between antibiotic use
and resistance was calculated. A positive correlation was
demonstrated between resistance and antibiotic consumption.
Differences in selection pressure accounted for geographical
variations in resistance; higher rates of resistance were
observed in European countries where antibiotic consump-
tion is moderate to high [1]. A comparison of outpatient
MLS use in Europe and the USA according to drug and
defined daily dose is presented in Table 2 [3].
Selective Pressure of Macrolides
Viridans group streptococci (VGS) are increasingly recog-
nized as being macrolide-resistant. A study was conducted
with 154 healthy Belgian adults to determine oropharyngeal
carriage of VGS resistant to macrolides and other common
antibiotics [2]. Seventy-one percent of adults in the study
presented with oropharyngeal carriage of macrolide-resistant
VGS, and 32% had more than one unique macrolide-resistant
isolate. Streptococcus mitis was the most common and most
resistant isolate, and was recovered from 51% of adults;
constitutive macrolide–lincosamide–streptogramin (cMLS) was
the predominant phenotype among the unique isolates [2].
A significant correlation was found between phenotypic
and genotypic profiles. The majority of cMLS isolates carried
erm(B), either alone or together with mef(A). S. mitis showed
the highest percentage prevalence of mef(A) and of erm(B) +
mef(A). Among tet genes, tet(M) was the most prevalent,
indicating a higher prevalence of tetracycline resistance
among macrolide-resistant isolates. The presence of the
same resistance determinants in both commensals and
pathogens suggested the possibility of interspecies gene
transfer [2].
TABLE 1. Outpatient macrolide, lincosamide and strep-
togramin use in Europe and the USA [3]
ATC
code
Corresponding
antibiotic (sub)class US DID (%)
European
DID (%)
J01F Macrolides, lincosamides
and streptogramins
3.52 (14.14) 2.98 (15.66)
Short-acting macrolides 0.43 (1.73) 0.48 (2.54)
Intermediate-acting macrolides 1.16 (4.66) 1.71 (8.96)
Long-acting macrolides 1.68 (6.74) 0.53 (2.77)
J01FF Lincosamides 0.25 (1.02) 0.16 (0.85)
J01FG Streptogramins <0.01 (0.00) 0.10 (0.55)
ATC, anatomical therapeutic chemical; DID, defined daily doses per 1000 inhab-
itants per day.
TABLE 2. Outpatient macrolide, lincosamide and strep-
togramin use in Europe and the USA according to drug and
defined daily dose per 1000 inhabitants per day (DID) [3]
Antibiotic
US DID
(%)
European
DID (%)
Highest
European
DID (country)
Lowest
European
DID (country)
Azithromycin 1.68 (6.7) 0.52 (2.7) 1.34 (Croatia) 0.04 (Sweden)
Clarithromycin 1.10 (4.4) 1.23 (6.5) 7.16 (Greece) 0.06 (Sweden)
Erythromycin 0.43 (1.7) 0.34 (1.8) 1.72 (UK) 0.01 (Bulgaria)
Clindamycin 0.25 (1.0) 0.14 (0.8) 0.70 (Hungary) <0.01 (Italy)
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A clinical trial with 224 healthy volunteers investigated the
direct effects of azithromycin and clarithromycin in promoting
carriage of macrolide-resistant oral streptococci and temporal
persistence of the selected resistant commensals [4]. At study
inception, prior to drug dosing, 30.1% of clarithromycin sub-
jects, 25.9% of azithromycin subjects and 27.5% of placebo
subjects were carriers of macrolide-resistant streptococci.
Following dosing, an increase in resistant pneumococci was
observed in both the azithromycin group and the clarithromy-
cin group; the increase persisted at levels significantly above
that in the placebo group for 6 months. Multivariate analysis
showed that macrolide exposure was the strongest variable
that was independently associated with the proportion of mac-
rolide-resistant streptococci. Gene analysis showed that the
use of clarithromycin was associated with a significant
decrease in mef carriage and a parallel increase in erm(B) and
tet(M) carriage. A two-fold increase was observed in the MIC
of erythromycin for macrolide-resistant streptococci that car-
ried mef after azithromycin exposure. The MIC90 increased
from 8 mg/L at day 0 to 16 mg/L at day 42 [4].
Emergence of Macrolide Resistance
An understanding of trends in antibiotic resistance may help
to explain the differences observed between the USA and
Europe. The PneumoWorld study (31 centres in eight
European countries) demonstrated that 28% (618/2279) of
isolates from Europe were macrolide-resistant. The erm(B)
gene caused resistance development in 84% of the isolates [8].
The results of the 3-year Prospective Resistant Organism
Tracking and Epidemiology for Ketolide Telithromycin
US surveillance (PROTEKT) study showed that mef was
responsible for most of the macrolide resistance in the USA,
as well as for changing trends in the mechanism of resistance
in the USA. A decrease in the number of isolates carrying
mef(A) was associated with a doubling of the number of
isolates carrying both mef(A) and erm(B) [9].
Coenen et al. described the changing trends in MLS use
in Europe. Total MLS use varied greatly among countries,
with the highest recorded use in Greece and the lowest in
Sweden. Marked variations across countries were observed
in the use of short-acting, intermediate-acting and long-acting
macrolides. Extreme seasonal variations in macrolide con-
sumption were observed among the European countries, and
suggested inappropriate use for familiar conditions such as
the common cold (viral upper respiratory tract infection),
influenza and bronchitis [10].
Dias and Canica demonstrated that the emergence of
erythromycin-resistant strains correlated well with the use
of azithromycin in Portugal, suggesting that antibiotic use is
linked with resistance [11].
Conclusions
Many surveillance systems have documented a positive cor-
relation between antibiotic consumption and resistance
development. Geographical variations in antibiotic use in
Europe substantiate the correlation. Countries with high
antibiotic consumption, e.g. those in southern and eastern
Europe, have higher rates of antibiotic resistance than coun-
tries with lower rates of antibiotic consumption, e.g. those in
northern Europe. Outpatient MLS use in Europe varies
greatly according to country and according to specific anti-
biotic. Macrolide resistance is mediated by erm(B) and mef(A)
alone or in combination. Selective pressure on resistance
expression by erm(B) and mef(A) has been demonstrated for
macrolides.
Ecological evidence exists linking antibiotic use and resis-
tance. Data collected from many European countries
show a positive correlation between use of penicillin or
erythromycin and the development of penicillin-resistant
S. pneumoniae.
Macrolide use was the single most important driver for
the emergence of macrolide resistance. High levels of con-
sumption of azithromycin in the USA and Canada correlated
with the predominance of mef-carrying S. pneumoniae. The
community-wide shifts in certain European countries,
Canada and the USA toward mef strains expressing higher
macrolide resistance might result from azithromycin con-
sumption.
Clarithromycin qualitatively selected the higher resistance-
conferring erm(B) gene. The higher consumption of clarithro-
mycin in Europe correlated with a predominance of erm(B)-
carrying S. pneumoniae. This may have implications that
include resistance to MLS and tetracyclines (co-carriage with
tet(M) on one genetic element).
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